Fc Receptor Homolog Antibodies And Uses Thereof
Provided herein are antibodies having the same epitope specificity as an antibody produced by the hybridoma cell line deposited with the American Type Culture Collection as hybridoma 4-2A6, 1-5A3, or 1-3B4. Further provided herein are methods of identifying and selecting cells that express FcRH1 or FcRH4. Methods of diagnosing and treating a subject with a malignancy of a hematopoietic cell lineage or an autoimmune disease and methods of modulating a humoral immune response in a subject are also provided herein. Further provided herein are polypeptides comprising one or more complementary determining regions of the disclosed antibodies and nucleic acids that encode the disclosed polypeptides.
1 . An antibody having the same epitope specificity as all antibody produced by the hybridoma cell line deposited under the American Type Culture Collection Accession Number ATCC#PTA-6236.
2 . An antibody produced by the hybridoma cell line deposited under the American Type Culture Collection Accession Number ATCC#PTA-6236.
3 - 6 . (canceled)
7 . A humanized version of the antibody of claim 1 , wherein the humanized version binds to an FcRH4 receptor molecule.
8 - 13 . (canceled)
14 . A human antibody that binds to the same epitope of an FcRH4 receptor molecule as the monoclonal antibody produced by the hybridoma cell line deposited under the American Type Culture Collection Accession Number ATCC#PTA-6236.
15 - 20 . (canceled)
21 . A hybridoma cell that produces the antibody of claim 1 .
22 . A cell of the hybridoma cell line deposited under the American Type Culture Collection Accession Number ATCC#PTA-6236.
23 . A method of diagnosing a malignancy of hematopoietic cell lineage in a subject, comprising:
a) contacting a biological sample of the subject with the antibody of claim 1 or fragment thereof under conditions that allows the antibody or fragment to bind to FcRH4 in the biological sample;
b) detecting binding by the antibody or fragment, changes in the binding as compared to binding in a control sample indicating a malignancy of hematopoietic cell lineage in the subject.
24 - 25 . (canceled)
26 . A method of identifying a hematopoietic cell that expresses FcRH4 in vitro, comprising:
a) contacting a biological sample with the antibody of claim 1 or fragment thereof under conditions that allow the antibody or fragment to bind to FcRH4 in the sample;
b) detecting the binding of the antibody or fragment, the binding identifying a hematopoietic cell that expresses FcRH4.
27 . (canceled)
28 . A method of treating a subject with a malignancy of a hematopoietic cell lineage, comprising administering to the subject a therapeutically effective amount of the antibody of claim 1 or a fragment thereof.
29 - 33 . (canceled)
34 . A method of diagnosing, an autoimmune disease in a subject, comprising:
a) contacting a biological sample of the subject with the antibody of claim 1 or a fragment thereof under conditions that allow the antibody or fragment to bind to FcRH4 in the biological sample;
b) detecting binding by the antibody or fragment, changes in the antibody binding as compared to binding in a control sample indicating an autoimmune disease in the subject.
35 . A method of treating an autoimmune disease in a subject, comprising contacting, with a therapeutically effective amount of the antibody of claim 1 or a fragment thereof one or more FcRH4 expressing cells of the subject.
36 - 49 . (canceled)
50 . An antibody having the same epitope specificity as an antibody produced by the hybridoma cell line deposited under the American Type Culture Collection Accession Number ATCC#PTA-6192.
51 . An antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC#PTA-6192.
52 - 55 . (canceled)
56 . A humanized version of the antibody of claim 50 , wherein the humanized version binds to an FcRH1 receptor molecule.
57 - 62 . (canceled)
63 . A human antibody that binds to the same epitope of an FcRH1 receptor molecule as the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC#PTA-6192.
64 - 69 . (canceled)
70 . A hybridoma cell that produces the antibody of claim 50 .
71 . A cell of the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC#PTA-6192.
72 . A method of diagnosing a malignancy of hematopoietic cell lineage in a subject comprising:
a) contacting a biological sample of the subject with the antibody of claim 50 or fragment thereof under conditions that allow the antibody or fragment to bind to FcRH1 in the biological sample;
b) detecting binding by the antibody or fragment changes in the binding as compared to binding in a control sample indicating a malignancy of hematopoietic cell lineage in the subject.
73 - 74 . (canceled)
75 . A method of identifying a hematopoietic cell that expresses FcRH1 in vitro, comprising:
a) contacting a biological sample with the antibody of claim 50 or fragment thereof under conditions that allow the antibody or fragment to bind to FcRH1 in the sample;
b) detecting the binding of the antibody or fragment, the binding identifying a hematopoietic cell that expresses FcRH1.
76 . (canceled)
77 . A method of treating a subject with a malignancy of a hematopoietic cell lineage, comprising administering to the subject a therapeutically effective amount of the antibody of claim 50 or a fragment thereof.
71 - 82 . (canceled)
83 . A method of diagnosing an autoimmune disease in a subject, comprising:
a) contacting a biological sample of the subject with the antibody of claim 50 or a fragment thereof under conditions that allow the antibody or fragment to bind to FcRH1 in the biological sample;
b) detecting binding by the antibody or fragment, changes in the antibody binding as compared to binding in a control sample indicating an autoimmune disease in the subject.
84 . A method of treating an autoimmune disease in a subject, comprising contacting, with a therapeutically effective amount of the antibody of claim 50 or a fragment thereof, one or more FcRH1 expressing cells of the subject.
85 - 98 . (canceled)
99 . An antibody having the same epitope specificity as an antibody produced by the hybridoma cell line deposited under the American Type Culture Collection Accession Number ATCC#PTA-6219.
100 . An antibody produced by the hybridoma cell line deposited under the American Type Culture Collection Accession Number ATCC#PTA-6219.
101 - 104 . (canceled)
105 . A humanized version of the antibody of claim 99 , wherein the humanized version binds to an FcRH1 receptor molecule.
106 - 111 . (canceled)
112 . A human antibody that binds to the same epitope of an FcRH1 receptor molecule as the monoclonal antibody produced by the hybridoma cell line deposited under the American Type Culture Collection Accession Number ATCC#PTA-6236.
113 - 118 . (canceled)
119 . A hybridoma cell that produces the antibody of claim 99 .
120 . A cell of the hybridoma cell line deposited under the American Type Culture Collection Accession Number ATCC#PTA-6219.
121 . A method of diagnosing a malignancy of hematopoietic cell lineage in a subject, comprising:
a) contacting a biological sample of the subject with the antibody of claim 99 or fragment thereof under conditions that allow the antibody or fragment to bind to FcRH1 in the biological sample;
b) detecting binding by the antibody or fragment, changes in the binding as compared to binding in a control sample indicating a malignancy of hematopoietic cell lineage in the subject.
122 - 123 . (canceled)
124 . A method of identifying a hematopoietic cell that expresses FcRH1 in vitro, comprising:
a) contacting a biological sample with the antibody of claim 99 or fragment thereof under conditions that allow the antibody or fragment to bind to FcRH1 in the sample;
b) detecting the binding of the antibody or fragment the binding identifying a hematopoietic cell that expresses FcRH1.
125 . (canceled)
126 . A method of treating a subject with a malignancy of a hematopoietic cell lineage, comprising administering to the subject a therapeutically effective amount of the antibody of claim 99 or a fragment thereof.
127 - 131 . (canceled)
132 . A method of diagnosing an autoimmune disease in a subject, comprising:
a) contacting a biological sample of the subject with the antibody of claim 99 or a fragment thereof under conditions that allow the antibody or fragment to bind to FcRH1 in the biological sample;
b) detecting binding by the antibody or fragment, changes in the antibody binding as compared to binding in a control sample indicating an autoimmune disease in the subject.
133 . A method of treating an autoimmune disease in a subject, comprising contacting, with a therapeutically effective amount of the antibody of claim 99 or a fragment thereof, one or more FcRH1 expressing cells of the subject.
134 - 147 . (canceled)
148 . A method of identifying an agent that alters modulation of the FcRH1 receptor comprising:
a) contacting a cell comprising the FcRH1 receptor with a test agent in the presence of the antibody of claim 50 or a fragment thereof; and
b) determining the level of modulation of the FcRH1 receptor as compared to a control cell comprising the FcRH1 receptor contacted with the antibody of claim 50 or a fragment thereof in the absence of the test agent, a difference in modulation indicating that the test agent alters modulation of the FcRH1 receptor by the antibody of claim 50 or a fragment thereof.
149 . A method of identifying an agent that alters modulation of the FcRH4 receptor comprising:
a) contacting a cell comprising the FcRH4 receptor with a test agent in the presence of the antibody of claim 1 or a fragment thereof, and
b) determining the level of modulation of the FcRH4 receptor as compared to a control cell comprising the FcRH4 receptor contacted with the antibody of claim 1 or a fragment thereof in the absence of the test agent, a difference in modulation indicating that the test agent alters modulation of the FcRH4 receptor by the antibody of claim 1 or a fragment thereof.